ClinicalTrials.gg
CompletedNCT02098772Custodiol-AVUpdated Jan 18, 2020

Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol

A Phase 3 interventional study of Custodiol-N and Custodiol in Aortic Valve Disease and Coronary Artery Disease (CAD), sponsored by Dr. F. Köhler Chemie GmbH. Completed at 6 sites in Germany. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by Dr. F. Köhler Chemie GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
530
Allocation
Randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Aortic Valve Disease with a site in Germany — 10 open to participants now, 13 under way, none of them phase 3. Aortic Valve Disease · Germany.

Enrollment
7th of 23
530 · median 155
Started
2014
the only one that year
Phase 3
Only one
of the 44
Registered
15th of 44
by date
Lead sponsor
1 of 44
Dr. F. Köhler Chemie GmbH

Among the 44 studies in Aortic Valve Disease with a site in Germany, this one is the 7th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2014, is the only one in phase 3, and was the 15th registered.

Aortic Valve Disease

234 studies on the registry are indexed under Aortic Valve Disease; 70 are open to participants now.

Browse Aortic Valve Disease studies →

Open to participants now

10 of the 44 studies in Aortic Valve Disease with a site in Germany are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Aortic Valve Disease with a site in Germany, or all of them as a file.
02

Study summary

The objective of this investigation is to compare the cardioprotective effects and safety of two cardioplegic solutions, HTK Cardioplegic Solution (Custodiol) and Custodiol-N in patients undergoing aortic valve surgery. The study design is a prospective, double blind, multicenter, randomized, Phase III comparison study intended to demonstrate superiority in surgical outcome between Custodiol and Custodiol-N as determined by CK-MB peak value 4-24 hours after opening of the aortic cross-clamp (primary endpoint), catecholamine requirement (cumulative dose) and cardiac Troponin T, occurrence of comorbid events postoperatively (e.g., myocardial infarction).

03

Conditions studied

  • Aortic Valve Disease
  • Coronary Artery Disease (CAD)

Keywords

  • aortic valve disease
  • coronary bypass surgery
  • cardioplegic solutions
04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients >/= 30 and \</= 85 years of age
  • Male or female with aortic valve disease
  • Able to understand character and individual consequences of the clinical trial and to provide written to participate in the study
  • Women of (ie, those who have not undergone a hysterectomy or who have not been for at least 12 consecutive months) must test negative for pregnancy prior to bypass surgery.

Exclusion criteria

Exclusion Criteria:

  • History of recent (\< 6 weeks) Q-wave myocardial infarction
  • \< 25% (as assessed by any one of the following: contrast ventriculography, multigated acquisition scanning [MUGA], or 2-D ECHO)
  • Patients on intra-aortic balloon devices or with history of previous coronary artery bypass surgery
  • Pregnant or lactating patients
  • Patients who have participated in any other studies within 30 days previous to enrollment
  • Patients in cardiogenic shock (defined as a systolic BP \< 90 mmHg for over one hour despite inotropic and chronotropic support)
  • Patients with severe chronic obstructive lung disease ( \< 50%)
  • Previous cardiac valvular disease (clinical relevant)
  • \<60 ml/min
  • Planned Ross-procedure, Mitral valve surgery, Aortic valve reconstruction, double valve surgery, other concomitant operations excluding coronary artery bypass surgery or closing a patent foramen ovale
  • Evidence of severe organic (e.g. cirrhosis of the liver) or psychiatric disease by history or physical examination
  • History of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction within 12 months of study enrollment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
530 participants (actual)

Study arms

  • Experimental
    Custodiol-N

    comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery

    Drug: Custodiol-N

  • Active comparator
    Custodiol

    comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery

    Drug: Custodiol

Interventions

06

What researchers measure

Primary outcomes

  1. peak value for CK-MB

    Time frame: measured at 4, 8, 12, 16, 20 and 24 hours after the release of the aortic cross clamp

Secondary outcomes

  1. Catecholamine requirement on SICU

    Time frame: within 24 hours (cumulative dose)

Other outcomes

  1. Safety parameters

    documentation and reporting of AE and SAE

    Time frame: from time of the study inclusion up to the follow-up visit on day 5

07

Study locations

6 sites
  • Klinik für Herzchirurgie, Universitätsklinikum Heidelberg
    Heidelberg, Baden-Württemberg 69120, Germany
  • Klinik für Herz- und Gefäßchirurgie GmbH, Herz-Kreislauf-Zentrum Rotenburg
    Rotenburg an der Fulda, Hessen 36199, Germany
  • Klinik für Herzchirurgie Universität Leipzig/ Herzzentrum Leipzig
    Leipzig, Sachsen 04289, Germany
  • Klinik für Herz- und Thoraxchirurgie Universitätsklinikum Jena
    Jena, Thüringen 07747, Germany
  • Klinik für Thorax-, Herz- und Gefäßchirurgie, Uniklinik der RWTH Aachen
    Aachen, 52074, Germany
  • Klinik für Gefäßchirurgie, Universitäres Herzzentrum am UKE Hamburg
    Hamburg, 20246, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2014 to primary completion in Nov 2018, 54 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2014
First posted
Mar 28, 2014
StartActual
May 2014
Primary completionActual
Nov 16, 2018
CompletionActual
Dec 2018
Last update
Jan 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02098772
Lead sponsor
Dr. F. Köhler Chemie GmbH
Responsible party
Sponsor
First posted
Mar 28, 2014
Start date
May 2014
Primary completion
Nov 16, 2018
Completion
Dec 2018
Last update
Jan 18, 2020

Study contacts

Gabor Szabó, Prof.
principal investigator · Department of Cardiac Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Custodiol-N solution · Histidine · Tryptophan · Ketoglutaric Acids · Mannitol · Sodium Chloride · Potassium Chloride · Magnesium Chloride · Calcium Chloride

Start the discussion